Bacterial topoisomerase inhibitors: Quinolones and beyond

Antimicrobials: New and Old Molecules in the Fight Against Multi-Resistant Bacteria

Volumn 9783642399688, Issue , 2014, Pages 307-326

  Pucci, Michael J ^a   Wiles, Jason A ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84913554744     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-39968-8_16     Document Type: Chapter

References (69)

1. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009) In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2, 440 clinical isolates. Antimicrob Agents Chemother 53:4915-4920
2. Almer LS, Hoffrage JB, Keller EJ, Flamm RK, Shortridge VD (2004) In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 48:2771-2777
3. Anderle C, Stieger M, Burrell M, Reinelt S, Maxwell A, Page M, Heide L (2008) Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 52:1982-1990
4. Angehrn P, Goetschi E, Gmuender H et al (2011) A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold synthesis and antibacterial properties. J Med Chem 54:2207-2224
5. Araake M, Hara T, Watabe H, Nishino T (2002) In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone. Jpn J Antibiot 55:778-790
6. Axten JM, Brooks G, Brown P et al (2004) PCT Int Appl WO004058144
7. Bax BD, Chan PF, Eggleston DS et al (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940
8. Black MT, Coleman K (2009) New inhibitors of bacterial topoisomerase GyrA/ParC subunits. Curr Opin Investig Drugs 10:804-810
9. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C (2008) Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 52:3339-3349
10. Bradbury BJ, Pucci MJ (2008) Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 8:574-581
11. Cambau E, Matrat S, Pan XS, Bettoni RRD, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM (2009) Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 63:443-450
12. Charifson PS, Grillot AL, Grossman TH et al (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51:5243-5263
13. Chu DT, Fernandes PB, Claiborne AK, Shen L, Pernet AG (1988) Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp Clin Res 14:379-383
14. Chung DT, Tsai TY, Chen SJ et al (2009) Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54:411-417
15. Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl Microbiol Biotechnol 92:479-497
16. Covington P, Davenport JM, Andrae D, O'Riordan W, Liverman L, McIntyre G, Almenoff J (2011) Randomized, double-blind, phase II, multicenter study evaluating the safety/ tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55:5790-5797
17. Domogala JM, Hagen SE (2003) Structure-activity relationships of the quinolone antibacterials in the new millennium: Some things change and some do not. In: Hooper DC, Rubenstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, DC
18. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2000) Quinolones action and resistance updated. Curr Top Med Chem 9:981-998
19. Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52:385-392
20. Eakin AE, Green O, Hales N et al (2012) Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob Agents Chemother 56:1240-1246
21. East SP, White CB, Barker O et al (2009) DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity. Bioor Med Chem Lett 19:894-899
22. Ellsworth EL, Tran TP, Showalter HDH et al (2006) 3-Aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. J Med Chem 49:6435-6438
23. Emmerson AM, Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51(Suppl S1):13-20
24. Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P (2010) Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations. J Antimicrob Chemother 65:2530-2533
25. Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM, Lynch AS (2011) Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob Agents Chemother 55:5522-5528
26. Fritsche TR, Biedenbach DJ, Jones RN (2009) Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother 53:1221-1224
27. Giannarini G, Tascini C, Selli C (2009) Prulifloxacin: Clinical studies of a broad-spectrum quinolone agent. Future Microbiol 4:13-24
28. Grossman TH, Bartels DJ, Mullin S (2007) Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 5:657-666
29. Haas W, Pillar CM, Zurenko GM, Lee JC, Brunner LS, Morris TW (2009) Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 53:3552-3560
30. Heide L (2009) Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol Adv 27:1006-1014
31. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H (2010) Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1613-1615
32. Hoshino K, Inoue K, Murakami Y, Kurosaka Y, Namba K, Kashimoto Y, Uoyama S, Okumura R, Higuchi S, Otani T (2008) In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 52:65-70
33. Huband MD, Cohen MA, Zurack M et al (2007) In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191-1201
34. Jones RN, Fritsche TR, Sader HS (2008) Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1, 149 recently collected clinical isolates. Antimicrob Agents Chemother 52:3763-3775
35. Keam SJ, Perry CM (2004) Prulifloxacin. Drugs 64:2221-2234
36. Kim EJ, Shin WH, Kim KS, Han SS (2004) Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem Toxicol 27:295-307
37. Kuramoto Y, Ohshita Y, Yoshida J, Yazaki A, Shiro M, Koike T (2003) A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2, 4-difluorophenyl) group. J Med Chem 46:1905-1917
38. Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC (2006) In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother 56:684-688
39. Lawrence L, Benedict M, Hart J, Hawkins A, Li D, Medlock M, Hopkins S, Burak E (2011) Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr A2-045a
40. Lesher GY, Froelic EJ, Gruett MD, Bailey JH, Brundage RP (1962) 1, 8-Naphthyridine derivatives. A new class of therapeutic agents. J Med Chem 91:1063-1065
41. Levasseur, P, Delachaume C, Lowther J, Hodgson J (2005) Minimum inhibitory concentrations (MIC) and mutation prevention concentrations (MPC) of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains. In: 45th interscience conference on antimicrobial agents and chemotherapy, abstr F-507
42. Levasseur, P, Girard AM, Lowther J (2007) Efficacy of oral NXL101, a novel topoisomerase inhibitor, against fluoroquinolone-susceptible (FQS) and-resistant (FQR) Streptococcus pneumoniae (Sp) strains in a mouse pneumonia model. In: 47th interscience conference on antimicrobial agents and chemotherapy, abstr F1-2125
43. Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA (2010) Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54:405-410
44. Lowther J, Levasseur P, Girard AM, Delachaume C, Borgonovi M, Hodgson J (2006) Efficacy of NXL101, a novel topoisomerase inhibitor, against multi-resistant Staphylococcus aureus in murine septicaemia and thigh muscle infections. In: 46th interscience conference on antimicrobial agents and chemotherapy, abstr F1-1999
45. Mani N, Gross CH et al (2006) In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 50:1228-1237
46. Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19(Suppl 1):20-29
47. Mitscher LA (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 105:559-592
48. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K (2010) In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 54:1955-1964
49. Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS (2011) Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother 55:5512-5521
50. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK (2003) In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 47:3260-3269
51. Oppegard LM, Hamann BL, Streck KR, Ellis KC, Fiedler HP, Khodursky AB, Hiasa H (2009) In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother 53:2110-2119
52. Owens RC Jr, Ambrose PG (2000) Clinical use of the fluoroquinolones. Med Clin North Am 84:1447-1469
53. Owens RC Jr, Ambrose PG (2005) Antimicrobial safety: focus on quinolones. Clin Infect Dis 41(Suppl 2):S144-S157
54. Pan XS, Gould KA, Fisher LM (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother 53:3822-3831
55. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH (2006) In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 50:2261-2264
56. Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA Jr, Bradbury BJ, Deshpande M (2007) In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant Gram-positive pathogens. Antimicrob Agents Chemother 51:1259-1267
57. Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M (2011) In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother 55:2860-2871
58. Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME (2011) Prulifloxacin: A review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents 37:283-290
59. Reck F, Alm R, Brassil P et al (2011) Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J Med Chem 54:7834-7847
60. Rubenstein E (2001) History of quinolones and their side effects. Chemother 47(Suppl 3):3-8
61. Ryder NS (2010) Discontinued drugs in 2008: Anti-infectives. Expert Opin Investig Drugs 19:1-21
62. Sherer BA et al (2011) Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorg Med Chem Lett 21:7416-7420
63. Tari LW, Bensen D, Tzross M et al (2011a) The discovery of potent, dual targeting pyrrolopyrimidine inhibitors of bacterial DNA gyrase B and topoisomerase IV with broad spectrum antibacterial activity. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr F1-1837
64. Tari LW, Bensen D, Tzross M et al (2011b) The discovery of novel, dual targeting inhibitors of bacterial DNA gyrase B and topoisomerase IV using pharmacophore-based crystallographic fragment screening. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr F2-1872
65. Tarral A, Rangaraju M, Merdjan H, Girard AM, Delachaume C, Lowther J (2007) Plasma bactericidal activity of NXL101 in healthy volunteers after single intravenous administration of 50 to 700 mg. In: 47th interscience conference on antimicrobial agents and chemotherapy, abstr A808
66. Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock T (2009) Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 25:1159-1169
67. Wang Q, Lucien E, Hashimoto A et al (2007) Isothiazoloquinolones with enhanced antistaphylococcal activities against multi-drug resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J Med Chem 50:199-210
68. Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 65:520-524
69. Wiles JA, Bradbury BJ, Pucci MJ (2010) New quinolone antibiotics: A survey of the literature from 2005 to 2010. Expert Opin Ther Patents 20:1295-1319